Educational guide · Phase 3 failed · not legally compoundable

A guide to larazotide acetate — regulatory status and buying considerations

Larazotide acetate (AT-1001 / INN-202) is not FDA-approved. Its pivotal Phase 3 trial for celiac disease (NCT03569007) failed in June 2022 and the sponsor filed bankruptcy. This page explains the regulatory status, what is and is not available, and how to evaluate any vendor if you choose to source it. We do not maintain a verified vendor directory for larazotide.

FDA status
Not approved
Phase 3 (celiac)
Failed June 2022
503A bulks list
Not listed
Typical dose
0.5 mg TID oral

Why we don’t list specific vendors for larazotide

Larazotide is in an unusual regulatory position even compared to other research peptides. Four facts together:

  • Not FDA-approved. No NDA on file for any indication. FDA Drugs@FDA database returns no record.
  • Phase 3 trial failed. The CeDLara trial (NCT03569007) was halted at interim analysis in June 2022 for futility on the primary endpoint.
  • Sponsor went bankrupt. 9 Meters Biopharma filed Chapter 7 in July 2023. There is no active commercial sponsor pursuing approval.
  • Not legally compoundable in the US. Larazotide is not on the FDA 503A bulks list, not a component of any FDA-approved drug, and has no USP monograph — failing all three statutory routes to legal pharmacy compounding.

The combination means there is no licensed pharmacy channel for larazotide. The only available supply is through research-peptide vendors operating under “for research purposes only” terms — research-chemical suppliers, not pharmacies, with no FDA, USP, or 503A oversight of product purity or labeling.

Vendor quality varies dramatically. At least one major research-peptide vendor was observed in 2026 listing larazotide with the wrong molecular weight and amino acid count on its product page (785.89 Da / 8 amino acids is correct). If a vendor cannot get the basic identity of a peptide right, third-party purity claims should be treated with significant skepticism. Larazotide has no third-party COA standard, and any certificate of analysis presented by a vendor is vendor-provided with limited independent verification.

If you choose to source larazotide anyway: how to evaluate a vendor

This guide does not endorse research-channel purchase. If you decide to proceed regardless, baseline evaluation criteria:

  1. Verify the basic chemistry on the product page. Larazotide acetate: 8 amino acids, molecular weight 785.89 Da, sequence Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (single-letter code: GGVLVQPG). PubChem CID 44146842 is the authoritative chemistry reference. Any vendor showing a different MW or amino acid count is unreliable on basic facts.
  2. Look for a third-party Certificate of Analysis. Vendor-issued COAs are common; truly independent (third-party lab) COAs are rare for larazotide. Treat vendor-issued COAs as marketing material, not validation.
  3. Beware injectable forms. Larazotide has zero human PK or efficacy data outside oral administration. Vendors offering injectable larazotide are selling a route with no clinical foundation — regardless of how it is marketed.
  4. Compare pricing against the active-ingredient cost. The Phase 3 clinical regimen is 0.5 mg TID = 1.5 mg/day = ~45 mg/month. Market prices for a month’s supply range $60–$200; significantly below or above that range is a flag.
  5. Read return and refund policies carefully. Most research-peptide vendors disclaim all medical use and have aggressive no-return policies. There is no consumer-product safety net.

Things to know before considering larazotide

  • For celiac disease, the standard of care is a strict gluten-free diet. Larazotide was studied as an adjunct for patients with persistent symptoms despite the diet — never as a replacement for it. Even when the Phase 2b signal looked promising, the FDA did not consider larazotide a replacement for dietary control. The Phase 3 failure removed even the adjunct case.
  • “Leaky gut” is not a settled clinical diagnosis. The intestinal-permeability concept has biological substance, but the term “leaky gut” as a standalone disease entity has limited consensus in mainstream gastroenterology. Larazotide’s mechanism on tight junctions is real; the clinical evidence for using it to treat undifferentiated “leaky gut” complaints is absent.
  • Larazotide is oral. Subcutaneous, intramuscular, and intranasal routes have zero human PK or efficacy data. Vendors promoting injectable larazotide are selling a route with no clinical foundation.
  • It interacts with the brush border, not your bloodstream. Larazotide is poorly absorbed by design. Drug-drug interactions are unlikely because the drug does not reach circulation in meaningful quantities — but this also means systemic conditions outside the gut are not biologically plausible targets.
  • Consult a physician — particularly a gastroenterologist — for any diagnosed GI condition. Adding an unapproved compound to celiac management without your GI’s input is risky for reasons beyond the drug itself: it can mask symptoms that need diagnostic follow-up.

What we recommend instead

There are no FDA-approved drugs that target intestinal tight junctions. For the conditions larazotide was studied for, the standard-of-care interventions are:

  • Celiac disease: Strict, lifelong gluten-free diet, with referral to a registered dietitian experienced in celiac management. Periodic monitoring of TTG IgA, follow-up endoscopy as clinically indicated, and screening for nutrient deficiencies (B12, folate, iron, vitamin D, zinc).
  • Non-celiac gluten sensitivity: Empirical gluten elimination under physician guidance after celiac and wheat allergy are ruled out.
  • Inflammatory bowel disease: Gastroenterologist-led care with FDA-approved biologics (TNF inhibitors, IL-12/23 inhibitors, integrin inhibitors), JAK inhibitors, or 5-ASA agents depending on subtype and severity.
  • IBS subtypes: Low-FODMAP diet trial, gut-directed psychotherapy, and FDA-approved IBS medications (linaclotide, lubiprostone, eluxadoline, rifaximin) targeted to subtype.

For practitioners interested in the underlying mechanism: zonulin antagonism remains a defensible therapeutic concept, but no FDA-approved zonulin antagonist exists, and no comparable molecule is in late-stage development as of this writing.

Authoritative sources

Stay informed

Monthly updates on FDA reclassification news, new dosing protocols, and calculator features. No spam, unsubscribe anytime.

Peptide updates + FDA alerts

Monthly peptide updates and important FDA alerts. No spam, unsubscribe anytime.

Editorial commitment

We list vendors only when we can verify their licensing, testing, and FDA standing. We do not maintain affiliate relationships with research peptide suppliers, and we do not maintain a vendor directory for larazotide because no FDA-overseen channel exists. Our editorial decisions are independent of commercial relationships.

Disclaimer: The Peptide Toolkit provides educational information only and is not a medical provider or pharmacy. We do not endorse off-label use of research peptides. Anyone considering use of an unapproved drug — particularly one whose pivotal Phase 3 trial failed — should consult a licensed gastroenterologist. This page contains no affiliate links to research peptide vendors. Last data review: May 13, 2026.